Clinical Trial Update: Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of toripalimab for clinically stage II-IIIB resectable non-small cell lung cancer with EGFR mutation and PD-L1 positive expression is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: RECRUITING